Chempartner Pharmatech (300149.SZ) announced its performance in the first half of the year, with a net loss of 62.9065 million yuan, an increase of 188.88%.

Chempartner Pharmatech (300149.SZ) released its semi-annual report for 2024, with revenue of 0.465 billion...

According to the semi-annual report for 2024 released by Chempartner Pharmatech (300149.SZ), the company's revenue was 0.465 billion yuan, a decrease of 16.56% year-on-year. The net loss attributable to shareholders of the listed company expanded by 188.88% to 62.9065 million yuan, while the net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, expanded by 121.75% to 64.0386 million yuan. The basic loss per share was 0.1263 yuan.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

睿智医药(300149.SZ)发布上半年业绩，净亏损6290.65万元，扩大188.88%

Chempartner Pharmatech (300149.SZ) announced its performance in the first half of the year, with a net loss of 62.9065 million yuan, an increase of 188.88%.

Risk Disclaimer

Statement